François Pognan

2.9k total citations · 2 hit papers
32 papers, 1.9k citations indexed

About

François Pognan is a scholar working on Molecular Biology, Computational Theory and Mathematics and Pharmacology. According to data from OpenAlex, François Pognan has authored 32 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Computational Theory and Mathematics and 8 papers in Pharmacology. Recurrent topics in François Pognan's work include Computational Drug Discovery Methods (9 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Animal testing and alternatives (5 papers). François Pognan is often cited by papers focused on Computational Drug Discovery Methods (9 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Animal testing and alternatives (5 papers). François Pognan collaborates with scholars based in Switzerland, United States and United Kingdom. François Pognan's co-authors include Matt Davison, Robert Tonge, Brian Middleton, Rachel Rowlinson, J. Young, Joanne Shaw, Edward Hawkins, John C. Lindon, Jeremy K. Nicholson and Muireann Coen and has published in prestigious journals such as Bioinformatics, PLoS ONE and Nature Reviews Drug Discovery.

In The Last Decade

François Pognan

32 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology

2001 706 citations Robert Tonge, Joanne Shaw et al. PROTEOMICS profile →
The evolving role of investigative toxicology in the pharmaceutical industry

2023 132 citations François Pognan, Mario Beilmann et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by François Pognan

Since Specialization

Citations

This map shows the geographic impact of François Pognan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Pognan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Pognan more than expected).

Fields of papers citing papers by François Pognan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Pognan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Pognan. The network helps show where François Pognan may publish in the future.

Co-authorship network of co-authors of François Pognan

This figure shows the co-authorship network connecting the top 25 collaborators of François Pognan. A scholar is included among the top collaborators of François Pognan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Pognan. François Pognan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The evolving role of investigative toxicology in the pharmaceutical industry breakdown → 2023 ·Nature Reviews Drug Discovery ·François Pognan, Mario Beilmann, Harrie C. M. Boonen, Andreas Czich, Gordon J. Dear, Philip Hewitt, Tomas Mow, Teija Oinonen, Adrian Roth, Thomas Steger‐Hartmann, Jean‐Pierre Valentin, Freddy Van Goethem, Richard Weaver, Peter Newham	132
2	Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib 2022 ·Current Research in Toxicology ·François Pognan, Chiara Buono, Philippe Couttet, Jean-René Galarneau, Yoav Timsit, Armin Wolf	7
3	Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes 2019 ·Journal of Pharmacology and Experimental Therapeutics ·François Pognan, Philippe Couttet, (unknown), (unknown), Yinuo Pang, Ronenn Roubenoff, Esther Sutter, Yoav Timsit, (unknown), (unknown), Gaëtane Woerly, Armin Wolf, U. Schramm	17
4	Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human 2018 ·Archives of Toxicology ·François Pognan, (unknown), Maria Papoutsi, David Ledieu, (unknown), Diethilde Theil, (unknown), Patrick J. Devine, (unknown), (unknown), André Cordier, Annabelle Heier, Carine Kolly, Andreas Hartmann, Salah‐Dine Chibout, Page Bouchard, Christian Trendelenburg	3
5	The eTOX Consortium: To Improve the Safety Assessment of New Drug Candidates 2017 ·Thomas Steger‐Hartmann, François Pognan	2
6	Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin 2016 ·Toxicology in Vitro ·Karin Brecht, (unknown), Philippe Couttet, Franziska Paech, Armin Wolf, Salah‐Dine Chibout, François Pognan, Stephan Krähenbühl, Marianne Uteng	17
7	Bile acids in drug induced liver injury: Key players and surrogate markers 2016 ·Clinics and Research in Hepatology and Gastroenterology ·Heiko S. Schadt, Armin Wolf, François Pognan, Salah‐Dine Chibout, Michael Merz, Gerd A. Kullak‐Ublick	65
8	Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans 2016 ·BioMed Research International ·Franck A. Atienzar, Eric A.G. Blomme, Minjun Chen, Philip Hewitt, J. Gerry Kenna, Gilles Labbe, Frederic Moulin, François Pognan, Adrian Roth, Laura Suter‐Dick, Okechukwu Ukairo, Richard Weaver, Yvonne Will, Donna M. Dambach	44
9	Ensuring confidence in predictions: A scheme to assess the scientific validity of in silico models 2015 ·Advanced Drug Delivery Reviews ·Mark Hewitt, Claire M. Ellison, M Cronin, Manuel Pastor, Thomas Steger‐Hartmann, J. A. Muñoz, François Pognan, Judith C. Madden	12
10	Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment 2014 ·Toxicology in Vitro ·Davide Germano, Marianne Uteng, François Pognan, Salah‐Dine Chibout, Armin Wolf	20
11	Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment 2012 ·PLoS ONE ·Caterina Vacchi‐Suzzi, Yasmina Bauer, Brian R. Berridge, Sandrine Bongiovanni, Kevin Gerrish, Hisham K. Hamadeh, Martin Letzkus, Jonathan J. Lyon, Jonathan G. Moggs, Richard S. Paules, François Pognan, Frank Staedtler, Martin Vidgeon-Hart, Olivier Grenet, Philippe Couttet	80
12	Inroads to Predict in Vivo Toxicology—An Introduction to the eTOX Project 2012 ·International Journal of Molecular Sciences ·Katharine Briggs, Montserrat Cases, David Heard, Manuel Pastor, François Pognan, Ferrán Sanz, Christof H. Schwab, Thomas Steger‐Hartmann, Andreas Sutter, (unknown), Joerg Wichard	36
13	Investigative safety science as a competitive advantage for Pharma 2012 ·Expert Opinion on Drug Metabolism & Toxicology ·Jonathan G. Moggs, Pierre Moulin, François Pognan, Dominique Brees, (unknown), Steve Busch, André Cordier, David Heard, Michael Kammüller, Michael Merz, Page Bouchard, Salah‐Dine Chibout	13
14	The Use of Rat Lens Explant Cultures to Study the Mechanism of Drug-Induced Cataractogenesis 2011 ·Toxicological Sciences ·(unknown), Lee Anne McLean, Chiara Buono, Pierre Moulin, Armin Wolf, Salah‐Dine Chibout, François Pognan, Steve Busch, Nandita Shangari, Elba de la Cruz, Maya Gurnani, Parul Patel, Albert Reising	6
15	Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies 2010 ·Leukemia Research ·Armin Wolf, Philippe Couttet, Min Dong, Olivier Grenet, Marcia I. Heron, Ursula Junker, (unknown), David Ledieu, Estelle Marrer, (unknown), Elke Persohn, François Pognan, Gilles‐Jacques Rivière, Daniel Roth, Christian Trendelenburg, Jeffrey Tsao, Danielle Roman	58
16	Preclinical evaluation of potential nilotinib cardiotoxicity 2010 ·Leukemia Research ·Armin Wolf, Philippe Couttet, Min Dong, Olivier Grenet, Marcia I. Heron, Ursula Junker, David Ledieu, Andreas Mahl, Estelle Marrer, Elke Persohn, François Pognan, Wei Zhou, Jeffrey Tsao, Danielle Roman	16
17	Mapping the epigenome — impact for toxicology 2009 ·Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions ·Jennifer Marlowe, Soon-Siong Teo, Salah‐Dine Chibout, François Pognan, Jonathan G. Moggs	13
18	Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: a long road with deep potholes 2007 ·Birkhäuser Basel eBooks ·François Pognan	10
19	Validation of an in vitro screen for phospholipidosis using a high-content biology platform 2006 ·Cell Biology and Toxicology ·(unknown), (unknown), François Pognan, Linda R. Barone, William Fieles, Paul J. Ciaccio	90
20	Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology breakdown → 2001 ·PROTEOMICS ·Robert Tonge, Joanne Shaw, Brian Middleton, Rachel Rowlinson, (unknown), J. Young, François Pognan, Edward Hawkins, (unknown), Matt Davison	706

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact